Skip to main content

Table 3

From: Tumor mica status predicts the efficacy of immunotherapy with cytokine-induced killer cells for patients with gastric cancer

Characteristics   Number Constituent ratio
Sex Male 66 69.5%
  Female 29 30.5%
Age <65 67 70.5%
  ≥65 28 29.5%
Histological grade G1-G2 48 50.5%
  G3-G4 47 49.5%
Stage II 44 46.3%
  III 51 53.7%
Adjuvant Chemotherapy Xelox, Folfox4 57 60.0%
  PF 38 40.0%
CIK cycles <5 54 56.9%
  ≥5 41 43.2%